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There have been a number of recent successes in the use of whole genome sequencing
and sophisticated bioinformatics techniques to identify pathogenic DNA sequence vari-
ants responsible for individual idiopathic congenital conditions. However, the success of
this identification process is heavily influenced by the ancestry or genetic background of
a patient with an idiopathic condition. This is so because potential pathogenic variants in a
patient’s genome must be contrasted with variants in a reference set of genomes made
up of other individuals’ genomes of the same ancestry as the patient. We explored the
effect of ignoring the ancestries of both an individual patient and the individuals used to
construct reference genomes. We pursued this exploration in two major steps. We first
considered variation in the per-genome number and rates of likely functional derived (i.e.,
non-ancestral, based on the chimp genome) single nucleotide variants and small indels in
52 individual whole human genomes sampled from 10 different global populations.We took
advantage of a suite of computational and bioinformatics techniques to predict the func-
tional effect of over 24 million genomic variants, both coding and non-coding, across these
genomes. We found that the typical human genome harbors ∼5.5–6.1 million total derived
variants, of which ∼12,000 are likely to have a functional effect (∼5000 coding and ∼7000
non-coding). We also found that the rates of functional genotypes per the total number of
genotypes in individual whole genomes differ dramatically between human populations.
We then created tables showing how the use of comparator or reference genome panels
comprised of genomes from individuals that do not have the same ancestral background as
a patient can negatively impact pathogenic variant identification. Our results have important
implications for clinical sequencing initiatives.
Keywords: clinical sequencing, congenital disease, whole genome sequencing, population genetics
INTRODUCTION
Whole genome sequencing (WGS) has enabled the search for
inherited DNA sequence variants that are responsible for idio-
pathic diseases affecting a number of individuals (Biesecker et al.,
2009; Lupski et al., 2010; Roach et al., 2010; Bainbridge et al.,
2011; Worthey et al., 2011; Lyon and Wang, 2012). The strategy for
identifying such variants is intuitive, as it involves two reasonable
assumptions: first, that the responsible variants are unique to the
individuals affected by the diseases and second, that these vari-
ants are likely to exhibit molecular effects pronounced enough to
be captured by available bioinformatic analyses of those variants
(Rope et al., 2011; Yandell et al., 2011). However, this strategy is not
necessarily trivial to implement. For example, determining that a
variant in the genome of a patient with an idiopathic condition is
unique to that patient requires contrasting variants in that patient’s
genome with variants observed on the genomes of a “reference” set
of individuals. The reliability of this comparison directly impacts
the ease and ultimate success of a search for a pathogenic variant,
and differences in the ancestry of the individuals whose genomes
are used in a reference set and the patient’s ancestry could influence
reliability in pronounced ways. In addition, the reliability of the
bioinformatics tools and other sources of information used to
make claims about the functional impact of a variant are also
crucial. Of course, many diseases, idiopathic or not, have a com-
plex molecular basis even though they exhibit pronounced clinical
phenotypic expressions and severe health consequences that on the
surface appear to be due to a singular, rare or overtly monogenic
genomic perturbation and thus may require a different strategy
for identifying their genetic determinants (Biesecker et al., 2009;
Gonzaga-Jauregui et al., 2012).
We considered the impact that the use of a reference set of
genomes obtained from individuals who do not have the same
ancestry as a patient would have on claims that a variant iden-
tified in a patient with an idiopathic condition is unique to
that patient. We also considered the influence of the use of dif-
ferent bioinformatic tools on the identification of pathogenic
variants when the ancestries of individuals used to construct
a reference genome panel vary. We did this by exploring both
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allele frequency differences and per-genome number and rate of
bioinformatically predicted functional variants – both coding and
non-coding – across multiple global populations from a WGS
perspective. The motivations for pursuing our study were straight-
forward: although many studies have explored the differences in
the frequencies of specific genetic variants between populations in
a way that has shed light on the contribution of those genetic dif-
ferences to actual phenotype frequency differences between those
same populations (Stephens et al., 1998; Evans et al., 2005), they
have not necessarily addressed issues concerning the identification
of pathogenic variations responsible for idiopathic conditions.
In this light, it is important to consider just how previous
studies have fallen short of providing comprehensive insight into
why searches for pathogenic variants must be sensitive to both
patient and genome reference panel member ancestries and bioin-
formatics strategies for characterizing the functional effects of
variants. A number of studies have explored the distant genealog-
ical relationships between individuals in populations that exhibit
phenotypic differences by either contrasting variant frequencies
between those populations (Rosenberg et al., 2002; Conrad et al.,
2006; Li et al., 2008), by assessing individual DNA sequence simi-
larities among individuals within and between those populations
(Nievergelt et al., 2007), or by investigating evidence for selec-
tion acting on variants based on population variant frequency
differences,(Nielsen et al., 2007; Pickrell et al., 2009) but have not
necessarily focused on the overt differences in the functional con-
tent of individual genomes, which is of great relevance to searches
for pathogenic variants influencing idiopathic conditions.
Recent studies by Bustamante and colleagues are an exception,
as they have considered differences in the frequencies of vari-
ants in coding elements with likely functional effects in ∼10,000
genes between European and African populations (Boyko et al.,
2008; Lohmueller et al., 2008). Specifically, they found evidence
for a greater proportion of homozygous, likely phenotypically
impactful, non-synonymous coding Single Nucleotide Variants
(ns cSNVs) in a sample of European American individuals com-
pared to a sample of African American individuals. They further
showed through simulation studies that the higher proportion of
likely functional ns cSNVs in the European population was con-
sistent with the effects of a historical bottleneck resulting from
out-of-Africa migrations. The results of these studies, and fur-
ther larger-scale surveys by the same group (Gravel et al., 2011),
could also provide a partial explanation for overall phenotypic
differences between African and European populations.
As important as the studies by Bustamante and colleagues and
related studies are (Pelak et al., 2010; Casto and Feldman, 2011;
Moore et al., 2011; Nelson et al., 2012; Tennessen et al., 2012), they
have important limitations. First, many focus on specific variant
types (e.g., SNVs) and, at least in the case of the focused surveys
by Bustamante and colleagues, coding variants only (Boyko et al.,
2008; Lohmueller et al., 2008; Gravel et al., 2011). Second, most
studies do not consider the use of a broad array of functional pre-
diction tools for the variants, but confine attention to a few tools.
Third, many studies do not necessarily consider a whole genome
perspective but rather focus on particular genomic regions or loci
(e.g., exons or candidate genes). Fourth, of the WGS studies inter-
rogating functional variant frequency and rate differences between
individuals or groups of individuals that have been pursued to
date, they do not exploit a common sequencing technology (Moore
et al., 2011), focus on a single disease or do not necessarily consider
the specific influence of ancestry on sources of genetic variation
(Pelak et al., 2010). Fifth, they do not emphasize rates of variation
on a per-individual whole genome basis but rather focus on con-
trasts involving population-level summary information regarding
frequencies and rates of variants. Sixth, they focus on contrasts
involving only a few populations and, in the context of an initial
study (Lohmueller et al., 2008), consider samples of European and
African American individuals who may harbor some degree of
admixture.
We sought to overcome limitations of previous studies by
exploring the differences in the genome-wide rates of non-
ancestral or “derived” variants (i.e., those variants in the human
lineage that deviate from the chimpanzee genome) that have a
predicted or likely functional effect between 52 individuals from
10 different global populations. Pronounced differences in the
functional content of genomes between individuals with differ-
ent ancestries would suggest that reference panels for pathogenic
searches must be made up of some individuals with same ances-
try as the patient, or the claim that a variant is unique to a patient
may be invalid. To assess this, we leveraged data generated by a sin-
gle sequencing technology generated at an appropriate sequencing
depth (∼60×). Our ultimate goal was to characterize differences
in the standing variation in contemporary populations that may be
of phenotypic relevance and ultimately impact searches for path-
ogenic variants in WGS analyses of individuals with idiopathic
conditions. More precisely, based on our data and functional vari-
ant analyses, we assessed the impact of ignoring the origins of
genomes used in reference panels created to facilitate the identifi-
cation the causative variants for rare and idiopathic conditions.
We did this in part by simulating genomes containing known
pathogenic variants and then determining the likelihood of identi-
fying that variant when the genomes of individuals with different
genetic backgrounds are contrasted to a genome harboring the
known pathogenic variant. As a byproduct of our investigation
we have created one of the largest collections to date of puta-
tive human functional DNA sequence variants. In addition, our
analyses further elucidate the breadth of functional variation in
contemporary global human gene pool. We emphasize that most
of our analyses considered both single nucleotide variants (SNVs)
as well as small insertion and deletion variants (indels) in both
coding and non-coding regions of the genome across individual
genomes, although for some of our analyses we focused on coding
variants only due to the lack of available contrasting data sets to
our own.
Because there are many steps in the analyses we pursued to
allow us to make conclusions about the need for sensitivity to
genetic background and ancestry, as well as bioinformatic tool
use, in the construction of reference panels exploited in searches
for pathogenic variants influencing idiopathic conditions, we give
a brief synopsis of each of these steps. The material presented
in the Sections “Materials and Methods” and “Results” is ordered
to follow these steps. We first obtained WGS data from individ-
uals thought to have diverse ancestral backgrounds and verified
this diversity using standard techniques. We then determined how
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the individual genomes differed from one another, essentially
identifying variable or “variant” genomic positions, by contrasting
each genome to the available human genome reference sequence,
which is flawed for our purposes for the reasons to be provided,
as well as the chimp genome, which is more appropriate for our
purposes. We then characterized the likely functional impact of
each variant position using what we believe is the most compre-
hensive set of bioinformatics tools assembled and applied in one
setting to date. We then contrasted the predicted functional con-
tent across the genomes of individuals with different ancestries
in terms of the absolute number of functional variants on each
genome, the rate of functional variants per total number of indi-
vidual genome variants, and the number of population-specific
variants on each genome and within each population. Finally, we
simulated settings in which we knew there was pathogenic variant
on an individual simulated patient’s genome and then performed
a bioinformatically guided search among all the variants on that
genome using reference panels made up of genomes from indi-
viduals whose ancestries both matched and did not match the
ancestry of the simulated patient.
MATERIALS AND METHODS
WHOLE GENOME SEQUENCE DATA FROM THE COMPLETE GENOMICS,
INC., PUBLIC DOMAIN REPOSITORY
We obtained publicly available complete genome sequence data
on 69 individuals of high quality (∼60× coverage, ∼97% bases
called) produced by Complete Genomics, Inc. (CGI) by down-
loading these data from the company’s website1. The assembly of
the genomes as well as variant calling for them has been described
in the literature (Drmanac et al., 2010; Roach et al., 2010). We
ultimately used the genotypes from the available “MasterVar Beta”
files provided by CGI directly and did not consider additional fil-
tering steps for the analysis of genotypes beyond those that went
into the construction of the public domain files. The 69 individ-
ual genomes consisted of 22 individuals of Northern European
ancestry (abbreviated here as CE for the CEPH or CEU HapMap
Population (Consortium, 2005; Frazer et al., 2007), 10 individuals
of Yoruban ancestry (YR), five individuals each of Mexican (ME),
and African ancestry living in Dallas (AS), four individuals each of
Japanese (JP), Han Chinese (CH), Italian (TS), East Indian (GI),
Maasai Kenyan (MK), and Luhya Kenyan (LW) ancestry, and three
individuals of Puerto Rican ancestry (PU). Thirteen CE individu-
als were the offspring of a couple of other CE individuals and were
excluded from the analysis. One YR individual was the offspring
of a YR couple and was excluded. The Puerto Rican individuals
were a mother-father-offspring trio and were also excluded. We
therefore ultimately considered 52 individuals from 10 different
global populations in our analysis (the data sets used that included
annotated variants are available from the authors). To show how
some of our results apply to other data sources, we also leveraged
sequence data available from the 1000 genomes project2. For one
set of analyses, we considered an ancestry assessment-verified (see
below) female European individual’s genome that was sequenced
1http://www.completegenomics.com/sequence_data/download-data/
2www.1000genomes.org/
by CGI independently of the 69 genomes we obtained from the
public domain.
ANCESTRY ASSESSMENT
We assessed the genetic background similarity of the 69 individ-
ual genomes downloaded from the CGI website, in addition to
the single independently sequenced European female’s genome, by
constructing identity-by-state (IBS) allele sharing similarity matri-
ces using 16,411 markers which had also been genotyped on 4,123
individuals in various public domain databases for whom ancestry
was known. We also calculated IBS allele sharing matrices based
on 19,208,882 variants determined from the WGS for the 52 indi-
viduals ultimately used on our analyses in addition to the parents
in the Puerto Rican trio. We then applied multidimensional scal-
ing (MDS) analysis to the sharing matrices to determine patterns
in genetic background similarity of the individuals (Reich et al.,
2008). Figure A1 in Appendix depicts the first two PCs for the
allele sharing determined through the use of the 16,411 markers
genotyped on the 4,123 reference individuals as well. Figure A2
in Appendix depicts the first two PCs the allele sharing matrix
determined through the use of the 19,208,882 markers identified
in the sequencing of the genomes of the 52+ 2 individuals. It is
quite clear from these analyses and plots that the 52 individu-
als whose genomes we are studying have diverse ancestries that
are consistent with the populations they are reported to repre-
sent. Additional analysis of the single European female’s genome
sequenced independently of the 52 genomes verified her European
ancestry (data not shown).
VARIANT ALLELE DETERMINATION
To catalog all position-specific differences (i.e., variants) between
the 52 genomes we considered two different strategies. We first
compared each genome to the human genome reference (version
hg18) and then determined the ancestral allele of each variant by
comparing the genomes to the available chimp genome reference.
We briefly describe each of these efforts below.
Human reference allele determination
We determined the sequence position of each variant site relative
build hg18 of the human genome provided on the UCSC browser
(Fujita et al., 2011). We did this for variant types we could deter-
mine from the CGI variant files in the public domain, including
SNVs, small insertion and deletion variants and multinucleotide
variants (i.e., small stretches of sequence where all the adjacent
nucleotides present differ from the reference genome). We could
thus determine the number and type of “non-reference” vari-
ants each of the 52 individual genomes we studied possessed. We
did not consider large structural variations nor did we consider
large copy number variants (CNVs) and other large repetitive
element-based variants. The use of the human genome refer-
ence for assessing inter-population differences in the frequency
and rate of functional variant is problematic since the available
UCSC Genome Browser human genome reference (hg18) is con-
structed from DNA of European individuals. Thus, the frequency
or “labeling” of nucleotides as variants that are “reference” or
“non-reference” in other populations would be dictated by what
is present on the genomes of individuals of European ancestry,
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if the human genome reference (hg18) is used. This can eas-
ily lead to interpretive biases regarding the relationships between
populations and genomic differences between those populations
(Hernandez et al., 2007; Boyko et al., 2008; Lohmueller et al.,
2008). In addition, as considered in the Section“Discussion,” func-
tional element determination based on single individual genomes
or genomes from individuals with a unique ancestry is problematic
due to structural differences in genomes that may impact the very
definition of a functional element (Balasubramanian et al., 2011).
Thus, we characterized variants as “non-reference” merely for the
sake of consistency with the literature and to allow us to determine
a reasonable and accepted approximation of the functional impact
of the variants we observed in the 52 genomes.
Ancestral allele determination
We also determined the ancestral allele of each variant site using
the PanTro2 build of the chimpanzee genome (Lohmueller et al.,
2008). In essence, we determined which allele at a variant site
among the 52 genomes we studied was present on the chim-
panzee genome (i.e., the “ancestral” allele) and which was not
(i.e., the “derived” allele). We determined ancestral alleles using
alignment information between the PanTro2 build of the chim-
panzee genome with the human genome (hg18) from the UCSC
Genome Browser (Chiaromonte et al., 2002; Kent et al., 2003;
Schwartz et al., 2003). When ancestral alleles could not be deter-
mined, we switched to alignments between the RheMac2 build
of the Macaque genome with the human genome (hg18) and
ignored positions when both alignments failed to reveal ances-
tral information. Ultimately, we pooled all non-reference variants
(determined from the comparison to the human genome refer-
ence hg18 as described above) seen across individuals and deter-
mined whether these variants matched ancestral alleles. In such
cases, these non-reference variants revealed that the deviation is
actually in the human reference genome (hg18) and not the non-
reference variant. Subsequently, all individuals that harbored the
non-reference variant no longer carried the variant while all other
individuals with the reference allele now contained a “derived” or
non-ancestral variant.
Given information about which variants were reference/non-
reference and ultimately ancestral or derived, we assigned, for
each individual genome at each variant site the labels “reference”
or “non-reference,” “ancestral” or “derived.” We then assigned
additional genotype labels to each genome as, e.g., “homozygous
derived,” “heterozygous,” or “homozygous ancestral” for all vari-
ant site positions for which we had ancestral allele information.
With this information, we could determine derived variants (likely
functional or not, see below for our assessment of the functional
impact of variants) that were only observed on a single genome
(genome-specific or “novel” variants within the context of our
dataset), derived variants that were only seen among the genomes
of individuals within a specific population (“population-specific”
alleles or variants), as well as the overall and population-specific
frequencies of the variants.
VARIANT FUNCTIONAL ELEMENT MAPPING
As noted, we mapped all variants to the UCSC Genome Browser
human reference genome, version hg18. Subsequently, we took all
variant positions and determined their proximity to known genes
and functional genomic elements using the available databases
from the UCSC Genome Browser (Fujita et al., 2011). All tran-
scripts of the nearest gene(s) were associated with a variant, and
functional impact predictions (see below) were made indepen-
dently for each transcript. If the variant fell within a known gene,
its position within gene elements (e.g., exons, introns, untrans-
lated regions, etc.) was recorded for functional impact predictions
depending on the impacted gene element. All variants falling
within an exon were analyzed for their impact on the amino
acid sequence (e.g., synonymous, non-synonymous, non-sense,
frameshift, in-frame, intercodon, etc.).
VARIANT FUNCTIONAL EFFECT PREDICTIONS AND ANNOTATIONS
Once the genomic and functional element locations of each
variant site were obtained, we leveraged a suite of bioinformat-
ics techniques and programs to “score” the derived alleles (i.e.,
derived variant nucleotides) for their likely functional effect on
the genomic element they resided in (Plumpton and Barnes, 2007).
Derived variants were assessed for potential functional effects for
the following categories: non-sense SNVs, frameshift structural
variants, splicing change variants, probably damaging (PD) non-
synonymous coding (nsc) SNVs, possibly damaging nscSNVs,
protein motif damaging variants, transcription factor binding site
(TFBS) disrupting variants, miRNA-BS disrupting variants, exonic
splicing enhancer (ESE)-BS disrupting variants, and exonic splic-
ing silencer (ESS)-BS disrupting variants. Details of the strategies
and algorithms used, as well as the criteria for labeling a variant
as “functional,” are provided in the Supplementary Material, but
suffice it to say that the functional prediction algorithms we used
exploit a wide variety of methodologies and resources to predict
variant functional effects, including conservation of nucleotides,
known biophysical properties of DNA sequence, DNA sequence
determined protein and molecular structure, and DNA sequence
motif or context pattern matching.
BETWEEN ANDWITHIN POPULATION FUNCTIONAL VARIANT
FREQUENCY AND RATE DATA ANALYSES
We compared the frequencies and rates of functional and non-
functional derived variants among the genomes of individuals
with different ancestries in a few different settings. The method-
ologies associated with each of these settings are described briefly
in isolation below.
General population comparisons
To compare frequencies and rates of different types of variants
(reference or derived; predicted functional or predicted non-
functional; coding, TFBS, etc.) across the 10 populations, graphical
displays and linear regression techniques were used. For the regres-
sion analyses, simple dummy variables for each of the 10 ancestral
populations were created (i.e., a value of 1.0 was assigned to an
individual genome that belonged to aspecific ancestral population
and 0.0 otherwise) and were used as independent variables in a
regression analysis with either the absolute number of variants
of a specific type on a genome, or the rate of that variant type
per all of an individual’s genomic variants, as a dependent vari-
able. For these comparisons, the YR (Yoruban) population was
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taken as a reference, such that the estimated regression coeffi-
cients reflect deviations from the YR population. We used Tukey’s
“Honestly Significantly Different (HSD)” method for evaluating
pairwise differences between individual populations for the dif-
ferent variant types from an analysis-of-variance (ANOVA). The
HSD method allowed us to make appropriate statistical inferences
given the number of pairwise population comparisons we made
(Braun, 1994).
Homozygous variant comparisons
We also compared the frequency and rate of variants of the dif-
ferent types that were homozygous across the populations using
regression methods analogous to those described above. We also
considered graphical displays of the frequency and rate differences
of homozygous variants across the populations.
Population-specific variant comparisons
We determined all the variants that were only found on genomes
of individuals with ancestries associated with three major conti-
nental populations. We first combined the genomes from CE and
TS subpopulations to form a European (EUR; n= 13) population,
the JP and CH subpopulations to form an Asian (ASN; n= 8)
population, and the YR, MK, and LW subpopulations to form an
African (AFR;n= 17) population. We excluded the AS subpopula-
tion from the formation of the African (AFR) population because
that population represents African American individuals sampled
from within the United States and therefore could reflect admixed
individuals. We then determined the number of variants that were
observed only within each population for each variant category,
and both aggregated the total number and rate of such variants in
each population also assessed the rate of such variants in each indi-
vidual genome in each population. z-tests assessing the equality of
these frequencies were performed. We also used regression analy-
ses to assess differences between the frequency and rates of African,
European, and Asian population-specific variants. The African
population was used as a reference and dummy variables for Euro-
pean and Asian ancestry were constructed. Pearson’s correlation
coefficients were calculated between rates of population-specific
functional variants relative to all population-specific variants as
well as relative to all variants.
SIMULATION STUDIES USING KNOWN PATHOGENIC VARIANTS
We assessed the impact of using inappropriately ancestry-matched
reference panels in efforts to identify patient-specific patho-
genic variants responsible for an idiopathic condition via simu-
lation studies. These simulation studies leveraged both the data
and insights associated with our assessment of global func-
tional variant diversity involving the 52 CGI genomes. We first
took 506 known Charcot-Marie-Tooth (CMT) syndrome caus-
ing variants from the OMIM database and computed their
Polyphen2(Ramensky et al., 2002; Adzhubei et al., 2010) and
SIFT scores (Ng and Henikoff, 2003; Kumar et al., 2009; or
rather, technically, 1.0-SIFT score, which we will refer to as the
“SIFT score”) and obtained their averages (average Polyphen2
score= 0.825, average SIFT score= 0.931, and average of the
average value of the Polyphen2/SIFT scores= 0.878) as well
as 567 known Cystic Fibrosis (CF) causing variants (average
Polyphen2 score= 0.769, average SIFT score= 0.891, and average
Polyphen2/SIFT score= 0.830) and “implanted” variants reflect-
ing these scores in a European individual’s whole genome sequence
variant list. Polyphen2 and SIFT are bioinformatics programs
implementing procedures for determining the likely functional
significance of non-synonymous coding SNVs and were including
in the suite of programs we used to characterize the likely func-
tional effect of variants (see above and Supplementary Material).
This European individual was sequenced by Complete Genomics,
Inc., in the same way as the 52 individuals taken from the CGI
repository, but was not part of that panel of 52 individuals.
By placing known disease-causing coding variants among the
other variants on this individual’s genome, we could see if we could
identify them as likely pathogenic and disease-causative among
all the other coding variants on that individual’s genome. This
activity was pursued by comparing these coding variants on this
individual’s genome to reference panel genomes made up of indi-
vidual genomes from among the 52 CGI genomes we studied with
the same and different ancestries. We pursued this using different
bioinformatics functional prediction tools to assess their impact
on pathogenic variant identification as well. We chose to explore
CMT variants and CF variants since CMT variants act in a dom-
inant fashion and CF variants act in a recessive fashion. We also
chose to leverage an individual not sequenced along with the 52
CGI public domain genomes since the variants on this individ-
ual’s have not been deposited into dbSNP and other databases and
thus many of them are not likely to have been studied by other
groups.
We also implanted CMT and CF variants with the scores
described above in the variant lists of a randomly chosen African
(taken from the AS population, which could reflect African Amer-
ican ancestry), Mexican, East Indian, and Puerto Rican genomes
from the total of the 69 individuals for which we had WGS
data from the CGI repository. We determined the number of
ns cSNVs (i.e., coding variants) that would be considered novel
(i.e., patient-specific) among these individuals’ sets of variants
with predicted functional scores from Polyphen2 (Ramensky
et al., 2002; Adzhubei et al., 2010) SIFT,(Ng and Henikoff, 2003;
Kumar et al., 2009), and the average Polyphen/SIFT score, greater
than those associated with the implanted, known disease-causing
CMT and CF mutations when compared to different reference
panel genomes sets. These reference panel sets included the 1000
Genomes Project exome sequencing data (as of October 2011;
Consortium, 2010; Gravel et al., 2011), both combined across all
populations considered in the Project and for each of the Euro-
pean, Asian, and African variant sets individually. We also created
reference sets for variants from all 52 individuals for which we had
WGS data as well as eight randomly chosen Europeans, Asians,
and Africans from these 52. Finally, we considered a combined
reference variant set that included the 1000 Genomes data and
the WGS data for the 52 individuals. We pursued these analyses by
assuming that the CMT mutation was dominant and the CF muta-
tion was recessive (i.e., for the CF mutation we considered as novel
only homozygous genotypes not observed in the reference panels
whereas for the CMT mutation we considered as novel any geno-
type that was not observed in the reference panels, homozygous,
or heterozygous).
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RESULTS
VARIANT IDENTIFICATION
From the 52 individual genomes we identified 24,277,549
“non-reference” variants that deviated from build hg18 of the
human reference genome represented in the UCSC browser (Man-
gan et al., 2009; Fujita et al., 2011). This included 19374542
SNVs, 1941800 insertions, 2282925 deletions, and 678282 multin-
ucleotide variants. We defined as “novel” a variant in one genome
that was not present on the other 51 genomes. Note that this def-
inition of “novel” is specific to our data set, since any variant we
observed may have been observed before in other studies. We did
not filter for novel variants using other publicly available data-
bases since the DNA samples from the 52 individuals sequenced
by CGI are available in the public domain and used often in poly-
morphism detection studies, such as the 1000 Genomes Project
(Consortium, 2010), and hence are likely to have genotype infor-
mation for them in publicly accessible databases such as dbSNP
(Day, 2010). In addition, it is known that different sequencing
platforms vary in their ability to identify deviant nucleotides, espe-
cially with respect to complex genomic regions, such as regions
with highly repetitive DNA (Harismendy et al., 2009; Moore et al.,
2011; Lam et al., 2012). A total of 4,596,517 variants among the
52 individuals (2921142 SNVs, 667458 insertions, 752180 dele-
tions, and 255737 multinucleotide variants and rearrangements)
were novel as defined. For each of the 24,277,549 non-reference
variant sites, we identified the ancestral allele using the chimp
and Macaque genome comparisons as described in the Section
“Materials and Methods.” We could not determine the ancestral
allele for 676,185 variants due to limitations in the available chimp
and Macaque reference assemblies. This amounted to 2.78% of
the total variants observed. We evaluated the likely functional
effect of the derived alleles as described in the Methods and cat-
aloged the number and rate of variant functional category types
per-genome.
GENERAL POPULATION COMPARISONS
We compared the frequency of variants in each of the defined
functional categories across the 10 populations via graphical and
linear regression analyses as described in the Section “Materials
and Methods”and found very dramatic and statistically significant
differences. Figure 1A provides a box plot depicting the differ-
ences in the absolute number of loci harboring non-reference
alleles for each population. There are between 500,000–750,000
more loci with non-reference alleles in the genomes of African
rather than non-African populations. Figure 1B depicts popula-
tion differences in the number of probably damaging (PD) (by
Polyphen2 designation) non-reference, non-synonymous coding
SNVs (ns cSNVs; see Materials and Methods; Sunyaev et al., 2001).
Each genome has, on average, 1650 loci that harbor a “PD” non-
reference ns cSNVs according to Polyphen2, with Africans having
∼1.23 times more PD non-reference ns cSNVs than non-African
populations (∼350 more ns cSNVs in absolute terms). Overall,
we found that virtually all forms of functional non-reference vari-
ants that we have characterized are significantly more frequent in
African rather than non-African populations (Tables S1 and S2
in Supplementary Material). We also determined the number of
“novel” non-reference variants on each individual genome (i.e.,
variants only found on an individual genome in our dataset) by
eliminating variants that were present on the other 51 genomes.
We find that, on average, a human genome has ∼103,000 loci
that harbor novel non-reference alleles, with non-African genomes
harboring∼10,000–50,000 less (Table S2 in Supplementary Mate-
rial). We found consistency in the effect sizes and statistical signifi-
cance of the African, European, and Asian populations, with some
deviations from the East Indian (GI) and Mexican (ME) popula-
tions that likely reflect the unique population origins (Tables S1
and S2 in Supplementary Material).
As noted, due to the fact that the human reference genome
available from the UCSC genome browser (Mangan et al., 2009)
is based on the DNA from individuals of European ancestry,
we did not want to rely on it for making claims about the fre-
quency and rates of functional variants on genomes from individ-
uals with different ancestries (see Materials and Methods; Boyko
et al., 2008; Lohmueller et al., 2008). We therefore considered
the frequency and rate of derived alleles across the genomes as
a complement to comparisons involving non-reference alleles.
Figures 1C,D depict the average number of derived variants on
the genomes of individuals from the 10 different ancestral pop-
ulations and the number of predicted PD derived ns cSNVs,
respectively. Figure 1C suggests that African genomes possess
∼6,000,000 loci that harbor derived alleles whereas non-African
genomes possess∼350,000 less. This suggests that there are a great
number of non-fixed derived variants in different human popu-
lations (i.e., variant sites for which ancestral and derived alleles
are segregating in the human population at large). Figure 1D
suggests that the number of loci that harbor PD derived ns
cSNVs is∼2850 in African genomes and∼250 less in non-African
genomes.
Table 1 presents the results of the regression analyses, and
provides the estimated regression coefficients and their signifi-
cance levels for each derived variant functional category. Note
that since the YR African population was taken as the refer-
ence population, a negative regression coefficient means that
genomes associated with a population have fewer variants, or a
smaller per-genome rate, for a derived variant category than the
YR population. The upper rows of Table 1 clearly suggest that
there are a greater number of derived variants or alleles within
African genomes across virtually every functional variant cate-
gories. The lower diagonal of Table 2 provides the results for
analyses comparing the 10 populations on a pairwise basis for
the total number of derived variants and suggests that although
there are differences between populations in the same continent,
they are not as pronounced as the differences between continental
populations. The fact that we have relatively small sample sizes
clearly affects this analysis. Tables S1–S6 in Supplementary Mate-
rial provide more in-depth analysis results for each setting we
considered.
HOMOZYGOUS VARIANT COMPARISONS
We tested for differences in the frequency and per-genome rate
of functional derived homozygous genotypes across the pop-
ulations. Figure 2 provides a graphical display of the results.
Figure 2A suggests that there is greater number of homozy-
gous loci with derived alleles in non-African populations, and
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FIGURE 1 | Boxplots reflecting the differences in the number and
rates of specific variant types across the 10 populations. (A)
Number of loci on individual genomes with at least one non-reference
allele (i.e., homozygous or heterozygous non-reference allele
genotypes); (B) Number of coding loci on individual genomes with at
least one non-reference allele that results in a non-synonymous amino
acid substitution that is predicted to have functional effect. (C) Number
of loci on individual genomes with at least one derived allele (i.e.,
homozygous or heterozygous derived allele genotypes); (D) Number of
coding loci on individual genomes with at least one derived allele that
results in a non-synonymous amino acid substitution that is predicted
to have functional effect.
Figure 2B suggests that there are a greater number of homozy-
gous loci with PD derived allele ns cSNVs in non-African pop-
ulations as well. Figures 2C,D suggest that there are a greater
number of homozygous loci with likely functional derived alle-
les of any type and ultimately a greater rate of homozygous
loci with likely functional derived alleles across entire individ-
ual genomes, respectively. This result – that despite the fact
that African genomes have a greater number of derived vari-
ants and derived functional variants, there is a greater number
and rate of homozygous derived and homozygous derived func-
tional variants among non-African genomes – is consistent with
the findings of Bustamante and colleagues (Lohmueller et al.,
2008). The bottom rows of Table 1 provide the regression analy-
sis results for homozygous derived variants and clearly show
that there is a significantly greater number and per-genome
rate of homozygous functional derived variants in non-African
populations.
Interestingly, although we found some evidence for consistency
in the deviations of the non-Yoruban African and non-African
populations from the Yoruban population with respect to numbers
and rates of functional variants, there were more subtle, but
statistically significant, differences in the total number and rates
of different derived variant functional categories, including the
number and rate of derived allele homozygous loci, between non-
African populations (Table 2, contrast the entries above and below
the diagonal). So, for example, the number of homozygous loci
harboring derived, likely functional alleles differs between Euro-
pean and Asian as well as East Indian populations, but not nec-
essarily between European populations and the admixed Mexican
population (upper diagonal entries of Table 2).
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POPULATION-SPECIFIC VARIANT COMPARISONS
To further characterize the population-level differences in the
functional content of individual genomes, we determined the
number of population-specific variants in European, Asian, and
African populations in a manner analogous to the approach taken
by Lohmueller et al. (2008) as described in the Section “Mate-
rials and Methods.” Table 3 provides the summary information
for the total number of population-specific variants as well as the
per-variant rate of different functional variant categories for each
population. The z-tests assessing the equality of derived functional
variant category frequencies are also provided in Table 3. As can
be seen, there are significantly higher rates of population-specific
likely functional derived variants per-genome across virtually
all functional variant categories in European and Asian popula-
tions relative to the African population, despite there being more
population-specific variation within the African population (top
row). However, there are virtually no significant differences in
these rates between European and Asian populations (Table 3, last
column).
As noted, in addition to comparing population summaries, we
also determined the rate of population-specific, likely functional
variants in each individual genome within each population. This
is important since sample size differences could impact the ability
to identify and test frequency differences of rare and population-
specific variants if only population summary statistics over all the
genomes are considered, as in Table 3. We find that there are higher
rates of functional variants among the population-specific variants
within European and Asian genomes relative to African genomes
despite the fact the rate of such variants is higher across all vari-
ants (i.e., not just population-specific variants) in African rather
than European and Asian genomes (Table S6 in Supplementary
Material).
SIMULATION STUDY RESULTS USING KNOWN PATHOGENIC VARIANTS
As emphasized in the Introduction, two factors go into the infer-
ence that a variant is likely to be pathogenic and causative of an
idiopathic condition: the variant must be unique to the patient
with the condition (i.e., “novel”) and it must be predicted to be
functional. Determining the novelty of a variant requires con-
trasting the patient’s genomic variants with variants on other
individuals’ genomes (i.e., a reference set of genomes). Determin-
ing functionality requires the use of bioinformatics techniques,
if not direct laboratory-based functional assays. Thus, in order
to determine the likely impact of our findings on searches for
pathogenic variants influencing idiopathic diseases, we consid-
ered how many ns cSNVs in five target individuals’ genomes (i.e.,
a European, African, Mexican, East Indian, and Puerto Rican sim-
ulated patient’s genome) would be considered as likely pathogenic
beyond known dominant-acting CMT syndrome-inducing vari-
ant and recessive-acting CF-inducing variants when compared to
different reference panel genome’ ns cSNV lists derived from the
52 individuals for which we had WGS information (see Materials
and Methods). We also considered the use of reference sets made
up of data from the 1000 genomes project3.
3www.1000genomes.org/
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Table 2 | Pairwise population comparisons usingTukey’s HSD method for the number of derived genotypes per-individual genome (below
diagonal) and number of functional homozygous derived genotypes (above diagonal).
Sample YR LW AS MK CE TS CH JP Gl ME
YR −30 20 −62 −772 −762 −907 −878 −606 −835
LW −83419 50 −32 −742 −732 −877 −848 −576 −805
AS −57488 25931 −82 −792 −782 −927 −898 −626 −855
MK −51149 32270 6339 −710 −700 −845 −816 −544 −773
CE −395516 −312097 −338028 −344367 10 −135 −106 166 −63
TS −375283 −291864 −317795 −324134 20233 −145 −116 156 −73
CH −428364 −344945 −370876 −377215 −32848 −53081 30 301 72
JP −442378 −358959 −384890 −391229 −46862 −67095 −14014 272 43
Gl −332702 −249282 −275214 281552 62815 42582 95663 109677 −229
ME −444922 −361503 −387434 −393773 −49405 −69639 −16558 −2544 −112220
Entries reflect the average differences with the populations listed in the second through eleventh columns subtracted from the populations listed in the first column.
Bolded entries=p-value<0.05; Bolded and Italicized entries=p-value<0.0005.
FIGURE 2 | Boxplots reflecting the differences in the number and rates of
specific variant types across the 10 populations. (A) Number of loci on
individual genomes that are homozygous for a derived allele; (B) Number of
coding loci on individual genomes that are homozygous for a derived allele
that results in a non-synonymous amino acid substitution that is predicted to
have functional effect. (C) Number of loci on individual genomes that are
homozygous for a derived allele that is predicted to have a functional effect;
(D) The rate of loci on individual genomes that are homozygous for a derived
allele that is predicted to have a functional effect (relative to all loci on
individual genomes with at least one derived allele).
We computed Polyphen2, SIFT, and the average Polyphen2 and
SIFT scores for the CMT and CF variants, all ns cSNVs variants
in each of the five target individual’s genomes and all ns SNVs in
each reference data set. We limited our assessment to cSNVs due to
the low coverage sequencing in non-coding regions pursued in the
1000 Genomes project. Table 4 provides the number of variants
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Table 3 | Frequency and rates (×10000) of population-specific variant types for African (AFR), European (EUR), and Asian (ASN) populations.
Variant type Populations z-test p-values
AFR EUR ASN AFR vs. EUR AFR vs. ASN EUR vs. ASN
Total number of variants: 7614850 2024886 1294731
Non-sense SNPs rate 0.500 0.840 0.842 6.931E-09 6.329E-07 4.910E-01
Frameshift structural variants rate 1.663 3.008 2.989 1.597E-34 6.239E-25 4.621E-01
Frameshift insertion rate 0.657 1.274 1.383 6.368E-19 1.089E-18 2.006E-01
Frameshift deletion rate 0.879 1.417 1.352 3.877E-12 1.584E-07 3.102E-01
Frameshift rearrangement rate 0.127 0.316 0.255 2.614E-09 2.228E-04 1.572E-01
Splicing change variants rate 1.707 2.514 2.379 4.655E-14 7.112E-08 2.223E-01
Probably damaging nscSNPs rate 10.103 15.472 15.602 1.136E-91 4.578E-69 3.853E-01
Possibly damaging nscSNPs rate 5.991 7.744 8.233 7.313E-19 3.064E-21 6.111E-02
Protein motif damaging variants rate 4.104 6.311 6.581 2.612E-39 3.043E-35 1.726E-01
TFBS disrupting variants rate 2.793 4.173 4.063 7.493E-69 2.764E-42 1.785E-01
miRNA-BS disrupting variants rate 0.948 1.170 1.081 2.405E-03 7.715E-02 2.286E-01
ESE-BS disrupting variants rate 5.835 7.260 7.283 1.696E-13 2.840E-10 4.689E-01
ESS-BS disrupting variants rate 2.460 3.013 2.865 6.435E-06 3.539E-03 2.232E-01
Total likely functional variant rate 23.718 34.906 35.436 8.999E-170 1.234E-132 2.128E-01
that would be considered both novel and as having a predicted
functional effect score at least a large as the known disease-causing
variants relative to all variants. Table 4 only provides the results of
our analyses when considering the dominant-acting CMT muta-
tion as the pathogenic variant to be identified. The upper rows
consider analyses that only use Polyphen2 scores, the middle rows
the use of SIFT scores, and the bottom rows the use of the aver-
age Polyphen2/SIFT scores as a way of assessing the functional
effects of the ns cSNVs. The columns correspond to the use of
different reference variant sets for determining the novelty of
a variant. Note that since the non-European target individuals
we assessed were part of the 69 WGS individuals that we stud-
ied we could not consider the use of a combined reference set
with 1000 Genomes and the 69 WGS genomes data (i.e., the
“ALLDB” column of Table 4). From Table 4, it can be seen that
one could expect some 194 ns cSNVs to be called as “novel” that
have Polyphen2 scores greater (and hence likely to be functional)
than the known CMT mutation for the European individual we
studied based on the use of a 1000 Genomes-derived European
reference ns cSNV panel; 680 if a 1000 Genomes-derived African
reference panel is used; and 439 if an eight member European
reference panel was constructed from the ns cSNVs from the
WGS data we studied. These would be out of a total of 1539 ns
cSNVs for this European individual. These numbers represent the
number of “false leads” one would have to deal with in trying to
identify the known causative variant (i.e., the “implanted” CMT
variant).
Table 4 also suggests that the use of different algorithms for
predicting the likely functional significance of variants makes a
difference (contrast the entries between the top, middle, and bot-
tom sets of rows), possibly the use of sequencing platforms (as
indicated by the small decrease in false positive results from the use
of the 1000 Genomes reference panels vs. the only eight member
WGS panel provided by the CGI data) and most importantly the
genetic background of the members in the panel (i.e., contrast the
columns that only consider the eight member panels derived from
the WGS data). We saw similar results when assessing the novelty of
homozygous variants and the scoring of the likely functional sig-
nificance of the known CF mutation (Table S7 in Supplementary
Material).
We also considered the impact of the addition of genomes to a
reference panel on potential “false lead” rates in pathogenic vari-
ant identification. Figure 3 depicts the relationship between the
number of variants with Polyphen2 scores greater than 0.8 that
would be determined as novel on a European (Figure 3A) and
African genome (Figure 3B) if reference panels were comprised of
increasing numbers of European,African, and Asian individuals. It
is quite clear from Figure 3 that including individuals with appro-
priate genetic backgrounds in reference panels for determining the
novelty of variants is crucial for reducing false leads and appropri-
ately ranking likely pathogenic variants. We found similar patterns
when considering analyses of an African individual’s genome-wide
ns cSNVs when using different (within) African population refer-
ence panels (Figure A3 in Appendix) but with a lesser overall effect
than if non-African individuals are used to construct the reference
panel.
DISCUSSION
We have assessed the differences in the genome-wide rates of
DNA sequence variants associated with different genomic func-
tional elements across 10 contemporary global populations. We
find striking evidence that historical population-level phenomena
of whatever sort, including possibly bottlenecks, unique migra-
tory patterns, admixture, natural selection, and random drift, have
left an imprint on the standing genetic variation that is likely to
influence phenotypic expression in these populations. In this light
our results are consistent with previous reports (e.g., Lohmueller
et al., 2008), but extend them to the entire genomes of individ-
uals from many different global populations. We also considered
many important functional variant categories and used genomes
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Table 4 |The number of ns cSNVs deemed “novel” with predicted functional consequence scores greater than that assigned a known CMT
syndrome-inducing variant as function of the reference panel used for five individual genomes of diverse ancestry.
Indiv Source ALLDB Polyphen score >0.825 (N =506)
All 1000k 1000k EUR 1000k ASN 1000k AFR All CGI CGI EUR CGI ASN CGI AFR
1000+ ∼500 ∼500 ∼500 52 8 8 8
European STSI 101/1593 179/1593 194/1593 317/1593 680/1593 174/1593 439/1593 588/1593 669/1593
African American CGI 185/1938 262/1938 795/1938 1068/1938 991/1938 995/1938 568/1938
Mexican CGI 169/1595 272/1595 362/1595 676/1595 491/1595 566/1595 681/1595
East Indian CGI 257/1685 329/1685 405/1685 669/1685 533/1685 538/1685 680/1685
Puerta Rican CGI 220/1664 287/1664 417/1664 683/1664 491/1664 576/1664 654/1664
Indiv Source ALLDB Sift score >0.931 (N =506)
All 1000k 1000k EUR 1000k ASN 1000k AFR All CGI CGI EUR CGI ASN CGI AFR
n=1000+ ∼500 ∼500 ∼500 52 8 8 8
European STSI 127/2593 232/2593 252/2593 394/2593 947/2593 221/2593 627/2593 843/2593 930/2593
African American CGI 241/3199 319/3199 1174/3199 1662/3199 1557/3199 1569/3199 828/3199
Mexican CGI 221/2565 311/2565 449/2565 963/2565 689/2565 831/2565 948/2565
East Indian CGI 353/2856 433/2856 537/2856 1070/2856 803/2856 835/2856 1016/2856
Puerta Rican CGI 289/2657 351/2657 502/2657 963/2657 676/2657 809/2657 900/2657
Indiv Source ALLDB Average score >0.878 (N =506)
All 1000k 1000k EUR 1000k ASN 1000k AFR All CGI CGI EUR CGI ASN CGI AFR
n=1000+ ∼500 ∼500 ∼500 52 8 8 8
European STSI 90/1269 157/1269 169/1269 268/1269 563/1269 146/1269 362/1269 478/1269 551/1269
African American CGI 148/1524 197/1524 628/1524 871/1524 800/1524 802/1524 466/1524
Mexican CGI 145/1229 204/1229 279/1229 556/1229 396/1229 455/1229 565/1229
East Indian CGI 213/1321 255/1321 315/1321 562/1321 428/1321 429/1321 556/1321
Puerta Rican CGI 173/1281 208/1281 309/1281 546/1281 391/1281 461/1281 531/1281
The numerator in each cell entry provides the number of ns cSNVs with functional consequence scores greater than the average of (N=506) known CMT mutations
that would be deemed novel on the basis of the different reference panels associated with each column of the table for the individuals’ whole genome variant lists
denoted in the “Indiv” column. The denominator provides the total number of ns cSNVs on each individual’s (“Indiv”) genome with scores higher than the CMT
mutation.
sequenced on a single platform and to great depth (∼60×). Impor-
tantly, we find that, on an individual genome-wide basis, there is
both an absolute and proportionately greater number and rate of
loci that are homozygous for derived alleles that are likely to be
functional in non-African populations (Lohmueller et al., 2008).
Our findings suggest that WGS will not only be of tremen-
dous value in future population genetic and human evolutionary
studies, but also that global human population differences in rates
of novel, deleterious, or functional variants must be taken into
account in certain clinical sequencing applications. Importantly,
our results emphasize the need for care in evaluating the novelty or
likely functional impact of variants in clinical sequencing studies
focusing on the identification of disease-inducing “pathogenic”
variants in an individual genome based on comparisons of that
genome to a reference panel of genomes (Biesecker et al., 2009).
This is the case because of the tremendous diversity of variants
across human populations, the existence of an abundance of likely
functional variants that are population-specific, and population
differences in the absolute number and rates of homozygous vari-
ants that are likely to impact phenotype expression. Thus, for
example, it might be highly problematic to evaluate the novelty
of variants in the genome of an African patient in order to fil-
ter out variants not likely to cause his or her unique disease by
comparing that individual’s genome to a reference panel that only
includes genomes from individuals with European ancestry. This
problem might be particularly pronounced in large urban centers
where individuals with a wide variety of ancestries may require
medical care.
There are a number of issues associated with our analyses that
require further consideration. First, although we used state-of-the-
field tools for assessing the potential molecular functional impact
of DNA sequence variations, many of these tools are not opti-
mal nor completely accurate and therefore require improvement
(Plumpton and Barnes, 2007; MacArthur et al., 2012). Despite
this, the consistency of the patterns we find with their use across
all functional categories is very unlikely to represent an artifact
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FIGURE 3 | Relationship between the number of ns cSNVs with
polyphen 2.0 scores >0.8 that would be declared as novel if a European
individual’s ns cSNVs were compared to a reference panel made up of
European, African or Asian individuals (A) or if an African individual’s ns
cSNVs were compared to a reference panel made up of European (light
dashed and dotted line), African (black solid line), or Asian individuals
(dashed light line) (B) as a function of the number of individuals in the
panel. Standard errors were computed by taking a randomly choosing the
number of individuals from our collection of European, African, and Asian
genomes given on the x axis.
induced by a drastic misclassification of the functional impact
of the variants. Second, although we avoided complete reliance
on a human reference genome for studying differences in vari-
ant types and rates across populations by determining ancestral
and derived alleles, many functional elements and functional pre-
diction algorithms rely on the available reference genome (e.g.,
defining TFBS and predicting TFBS disrupting variants) and hence
may not be adequately evaluating the functionality of specific vari-
ants due to structural and sequence context differences that exist
between individuals (Balasubramanian et al., 2011). However, as
SIFT and Polyphen2 exploit cross-species nucleotide conservation
information, we are confident that our analyses of coding variants
is not affected as much by this issue. Third, we defined derived
and ancestral alleles using the available chimp and macaque refer-
ence genomes (Boyko et al., 2008; Lohmueller et al., 2008). These
reference genomes – like all species reference genomes – are likely
incomplete and harbor some level of inaccurate nucleotide assign-
ments. In addition, polymorphism among individual chimps and
macaques are not reflected in the chimp and macaque refer-
ence genomes, making it hard to know which alleles at these
polymorphic sites actually reflect the consensus ancestral allele
for the reference. Thus, some of the variants we characterized as
derived or ancestral may be inaccurate, but not likely to a degree
that would invalidate our results. Fourth, importantly, we did not
consider phase information when evaluating the functional con-
tent of the human genomes we analyzed, as phase information is
currently hard to obtain without additional resources (e.g., family
members of individuals sequenced; Tewhey et al., 2011). Thus, we
were not in a position to evaluate the likely impact or popula-
tion differences of potentially functional compound heterozygous
sites in the human genome – sites which may be of particular
relevance for human phenotypic expression and disease studies
(Tewhey et al., 2011). Fifth, we had relatively small sample sizes
(e.g., 4–5 genomes from some populations) clearly limiting our
ability to detect subtle variant frequency differences and make
broad generalizations about variant frequencies in the population
at large.
Despite the shortcomings of our study, we believe studies such
as ours will help usher in an era of routine WGS for human pop-
ulation and clinical studies. In order to fully develop such studies,
however, greater emphasis on the construction of ubiquitous and
accessible whole genome reference sequence databases must be
made, with sensitivity to the need to populate those databases
with genomic information from individuals with different ances-
tries (Bustamante et al., 2011). The number of individuals needed
of each ancestry to be reliable for determining the likelihood that
a particular variant is unique to a patient with an idiopathic con-
dition is an open question, but our analyses, as well as other recent
studies (Pelak et al., 2010), suggest that there is diminishing returns
in adding more and more genomes to a reference panel in order to
cut down on the number of variants falsely inferred as novel, pos-
sibly after as few as 8–15 individual genomes. In addition, better
methods for predicting the functional consequences of variants
of unknown significance are needed, as are methods for lever-
aging such predictions in more sophisticated pathogenic variant
identification strategies (Ionita-Laza et al., 2011; Rope et al., 2011;
Torkamani et al., 2011; Yandell et al., 2011).
Our results also bear on DNA sequence-based searches for rare
variants that contribute to non-idiopathic common, chronic con-
ditions such as diabetes, cancer, and heart disease (Bansal et al.,
2010). For example, many statistical methods for testing the con-
tribution of rare variants to a disease weight variants by their
frequency and their likely functional impact score, both activities
of which should be informed by the knowledge of genome-wide
rates of variants across populations and the behavior of bioin-
formatics tools for assessing variant functionality. In this light,
our study may motivate larger and more sophisticated studies
investigating the impact of population-level genetic phenomena
on the utility of, and necessary infrastructure for, clinical DNA
sequencing.
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APPENDIX
HUMAN POPULATION DIFFERENCES IN RATES
Ancestry assessment
We assessed the genetic background similarity of the individuals by
constructing identity-by-state (IBS) allele sharing similarity matri-
ces using 16,411 markers which had also been genotyped on 4,123
individuals in various public domain databases for which ancestry
information on the individuals in those databases was recorded.
We also calculated IBS allele sharing matrices based on 19,208,882
variants determined from the whole genome sequencing for the
52 individuals in addition to the parents in the Puerto Rican trio.
We then applied multidimensional scaling (MDS) analysis to the
sharing matrices to determine patterns in genetic background sim-
ilarity of the individuals (Reich et al., 2008). Figure A1 in Appendix
depicts the first two axes for the allele sharing determined through
the use of the 16,411 markers genotyped on the 4,123 reference
individuals as well. Figure A2 in Appendix depicts the first two PCs
the allele sharing determined through the use of the 19,208,882
markers identified in the sequencing of the genomes of the 52+ 2
individuals.
Functional annotations
Genomic elements and conservation. All variants were associ-
ated with conservation information in two ways. First, variants
were associated with conserved elements from the phastCons con-
served elements (28 way, 44 way, 28 way Placental, 44 way Placental,
and 44 way Primates; Siepel et al., 2005). These conserved elements
represent potential functional elements preserved across species.
Conservation is also assessed at the specific nucleotide positions
impacted by the variant using the phyloP method (Pollard et al.,
2010). The same conservation levels as phastCons are used in order
to gain higher resolution into the potential functional importance
of the specific nucleotide impacted by the variant.
Transcription factor binding sites and predictions. All variants,
regardless of their genomic position, were associated with pre-
dicted transcription factor binding sites (TFBS) and scored for
their potential impact on transcription factor binding. We pre-
computed predicted TFBS by utilizing the human transcription
factors listed in the JASPAR and TRANSFAC transcription fac-
tor binding profile to scan the human genome using the MOODS
algorithm (Wingender et al., 1996; Wasserman and Sandelin, 2004;
Korhonen et al., 2009). The probability that a site corresponds to
a TFBS is calculated by MOODS based on the background distri-
bution of nucleotides in the human genome. We call TFBS at a
relaxed threshold within (p-value< 0.0002) in conserved, hyper-
sensitive, or promoter regions, and at a more stringent threshold
(p-value< 0.00001) for all other locations in order to capture
sites that are more likely to correspond to true functional TFBS.
Conserved sites correspond to the phastCons conserved elements,
hypersensitive sites correspond to Encode DNASE hypersensi-
tive sites annotated in UCSC genome browser, while promoters
correspond to regions annotated by TRANSPro,and 2 kb upstream
of known gene transcription start sites, identified by SwitchGear
Genomics ENCODE tracks. The potential impact of variants
on TFBS were scored by calculating the difference between the
mutant and wild-type sequence scores using the position weighted
matrix method described in Stormo (2000) and shown to identify
regulatory variants in Andersen et al. (2008).
Splicing predictions. Variants falling near exon-intron bound-
aries were evaluated for their impact on splicing by the maximum
entropy method of maxENTscan (Yeo and Burge, 2004). Maxi-
mum entropy scores were calculated for the wild-type and mutant
sequence independently, and compared to predict the variants
impact on splicing. Changes from a positive wild-type score to
a negative mutant score suggest a splice site disruption. Variants
falling within exons were also analyzed for their impact on exonic
splicing enhancers and/or silencers (ESE/ESS). We determine the
number of ESE and ESS sequences created or destroyed based on
the hexanucleotides reported as potential exonic splicing regu-
latory elements (Stadler et al., 2006) and shown to be the most
informative for identification of splice-affecting variants (Woolfe
et al., 2010).
microRNA binding sites. Variants falling within 3′UTRs were
analyzed for their impact on microRNA binding in two differ-
ent manners. First, all 3′UTRs were associated with pre-computed
microRNA binding sites using the targetScan algorithm and data-
base (Lewis et al., 2005). Variant 3’UTR sequences were rescanned
by targetScan in order to determine if microRNA binding sites
are lost due to the impact of the variation. Second, the binding
strength of the microRNA with its wild-type and variant binding
site is calculated by the RNAcofold algorithm to return a ∆∆G
score for the change in microRNA binding strength induced by
introduction of the variant (Hofacker, 2003).
Protein coding variants. While interpretation of frameshift
and nonsense mutations is fairly straightforward, the functional
impact of non-synonymous changes and in-frame indels or
multi-nucleotide substitutions is highly variable. We utilized the
PolyPhen-2 algorithm, which performs favorably in comparison to
other available algorithms, for prioritization of non-synonymous
single nucleotide substitutions (Adzhubei et al., 2010). A major
drawback to predictors such as PolyPhen-2 is the inability to
address more complex amino acid substitutions. To address this
issue, we also generated the LogR. E-value score of variants, which
is the log ratio of the E-value of the HMMER match of PFAM
protein motifs between the variant and wild-type amino acid
sequences (Clifford et al., 2004). This score has been shown to
be capable of accurately identifying known deleterious muta-
tions. More importantly, this score measures the fit of a full
protein sequence to a PFAM motif, therefore multi-nucleotide
substitutions are capable of being scored by this approach.
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FIGURE A1 | Multidimensional scaling plot of the similarity of the 54
unrelated individuals with complete genome data. (A) The 54
individuals (black dots) overlaid on 4,123 individuals of known ancestry
based on 16,411 ancestry informative markers. The individuals with known
ancestries were obtained from public repositories and are color coded by
continent with shading indicating subpopulations within those continents
(Blue, Europeans; Yellow, Yorubans; Purple, East Asians; Red: Native
Americans; Green: Central Asians; Grey: African Americans). (B)
Multidimensional scaling plot of the similarity of the content of 54
individuals with complete individual genomes without the overlay of other
individuals. Color coding for these 54 individuals based on their known
ancestries is given in the inset.
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FIGURE A2 | PCA plot of the similarity of the 54 unrelated
individuals with complete genome data based on 19,208,882
SNVs obtained from the complete sequencing data without
regard to a reference panel of individuals with global
ancestries (shading according to population is provided by the
inset).
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FIGURE A3 | Relationship between the number of ns cSNVs with
polyphen 2.0 scores>0.8 that would be declared as novel an African
individual’s ns cSNVs were compared to a reference panel made up of
European, AfricanYoruban or African non-Yoruban individuals as a
function of the number of individuals in the panel. Standard errors were
computed by taking a randomly choosing the number of individuals from our
collection of European, African Yoruban, or African non-Yoruban individuals
given on the x axis.
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